Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Tonix in the News
  • Tonix Sponsored News
  • IR Events
  • Email Alerts
  • Op-Eds
Sep 6, 2022 7:00am EDT

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)

Aug 22, 2022 7:00am EDT

Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID

Aug 9, 2022 7:00am EDT

Tonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor Summit

Aug 8, 2022 7:00am EDT

Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Aug 2, 2022 7:00am EDT

Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication

Aug 1, 2022 7:00am EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain

Jul 28, 2022 7:00am EDT

Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection

Jul 25, 2022 7:00am EDT

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Jul 11, 2022 7:00am EDT

Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder

Jul 6, 2022 7:00am EDT

Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • …
  • …Page 69
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.